Pfizer COVID-19 vaccine candidate over 90 percent effective, Phase III study shows
The COVID-19 vaccine candidate BNT162b2, made by Pfizer and BioNTech,…
The COVID-19 vaccine candidate BNT162b2, made by Pfizer and BioNTech, has demonstrated over 90 percent efficacy in its first interim analysis during its Phase III trial.